ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17,898.50 |
| 52 Week High | US$22,900.00 |
| 52 Week Low | US$6,435.00 |
| Beta | 0.56 |
| 1 Month Change | -7.24% |
| 3 Month Change | -15.18% |
| 1 Year Change | 135.93% |
| 3 Year Change | 914.65% |
| 5 Year Change | n/a |
| Change since IPO | 973.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABBV | AR Biotechs | AR Market | |
|---|---|---|---|
| 7D | 2.6% | 0% | 0% |
| 1Y | 135.9% | 0% | 0% |
Return vs Industry: ABBV exceeded the AR Biotechs industry which returned -4.8% over the past year.
Return vs Market: ABBV underperformed the AR Market which returned 291% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in AR Market | 0% |
| 10% least volatile stocks in AR Market | 0% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | AR$262.00t |
| Earnings (TTM) | AR$4.21t |
| Revenue (TTM) | AR$47.41t |
62.3x
P/E Ratio5.5x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$54.32b |
| Cost of Revenue | US$16.73b |
| Gross Profit | US$37.59b |
| Other Expenses | US$32.77b |
| Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.72 |
| Gross Margin | 69.21% |
| Net Profit Margin | 8.87% |
| Debt/Equity Ratio | 573.6% |
How did ABBV perform over the long term?
See historical performance and comparison